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The current obesity pandemic, which is in part a consequence of social trends toward 
higher energy intake and reduced energy expenditure, is expected to result in type 2 
diabetes (T2DM) and considerable downstream morbidity, mortality and incremental 
costs to healthcare systems around the world [1]. The number of T2DM cases is 
increasing at a worrisome rate and is expected to double within the next 20 years. 
However, the molecular mechanisms that underlie individual changes in the 
predisposition to obesity and T2DM remain obscure. 
The identification of DNA variants influencing disease predisposition will deliver 
clues to the processes involved in disease pathogenesis. This would not only spur 
translational innovation but also provide opportunities for personalized medicine 
through stratification according to an individual’s risk and more precise classification of 
the disease subtype. Linkage analysis and large-scale association studies have revealed 
many loci that confer susceptibility to T2DM [2, 3].  
Because microRNAs (miRNAs) have been shown to be another layer of gene 
regulation, it is not surprising that they are also involved in the development of 
obesity-induced insulin resistance and T2DM [4]. miRNAs are endogenous, 
single-stranded, small, ~22-nucleotide noncoding RNAs. miRNAs are generally 
regarded as negative regulators of gene expression by inhibiting translation and/or 
promoting mRNA degradation by base pairing to complementary sequences within the 
3’ untranslated region (3’UTR) of protein-coding mRNA transcripts [5]. However, 
recent studies have suggested that miRNA-binding sites are also located in 5' 
untranslated regions (UTRs) or open reading frames (ORFs), and the mechanism(s) of 
miRNA-mediated regulation from these sites has not been defined [6, 7]. The first 
miRNA assigned to a specific function in metabolism was identified in Drosophila 
melanogaster, where loss of miRNA (miR)-14 increases body fat content [8]. Since then, 
a variety of miRNAs have been discovered in the regulation of glucose and lipid 
metabolism [9-12]. The fact that T2DM susceptibility genes discovered by 
whole-genome association studies were located in non-coding regions supports the 
possibility that non-coding RNAs, such as miRNAs, may also contribute to the 
development of obesity and T2DM [13, 14]. 
In order to understand the function of miRNAs in obesity and T2DM, the 
Brüning’s group searched for miRNAs upregulated in liver associated with specific 
feeding conditions [15]. Upregulation of miR-143 was also confirmed in the liver of 
db/db mice and diet-induced obese mice. miR-143 and miR-145 form a small gene 
cluster on mouse chromosome 18 and miR-145 was also upregulated in the liver and 
pancreas of obese mice, whereas the pattern of regulation differs in other tissues, 
including white and black adipose tissue. 
To investigate whether increased hepatic miR-143 expression contributes to the 
metabolic phenotype arising from obesity in vivo, Jordan and colleagues generated 
time-controlled, doxycycline-inducible miR-143 transgenic mice. Although miR-143 
transgenic mice (miR-143
DOX
) after four weeks of doxycycline treatment showed 
conditional overexpression of miR-143, predominantly in liver and brown adipose 
tissue, there was no change in body weight, fat mass or circulating plasma leptin 
concentrations. However, overexpression of miR-143 did result in a dysregulation of 
glucose metabolism. Doxycycline-treated miR-143
DOX
 mice exhibited impaired glucose 
and insulin tolerance without any change in-cell function. 
To further investigate the molecular basis of insulin resistance in miR-143
DOX
 mice, 
the authors analyzed insulin-stimulated signaling in liver and skeletal muscle. 
Conditional miR-143 overexpression impairs insulin-stimulated AKT activation in the 
liver but not in skeletal muscle.  
To confirm the involvement of miR-143 in insulin resistance and inhibition of 
insulin-stimulated AKT activation, the authors investigated whether miR-143 deficiency 
can protect against obesity-induced insulin resistance in vivo. miR-143-145-deficient 
and control mice were exposed to high-fat feeding, and glucose metabolism as well as 
hepatic insulin signaling was compared in these mice. Both glucose tolerance and 
insulin sensitivity was significantly improved in obese miR-143-145-deficient mice 
when compared with controls. Insulin sensitivity was paralleled by increased 
insulin-stimulated phosphorylation of AKT in the liver of obese miR-143-145-deficient 
mice, compared with controls, which was consistent with the results for conditional 
miR-143 overexpression. 
The recent work of Jordan and colleagues represents an important breakthrough in 
the determination of the molecular target of miR-143 by employing in vivo stable 
isotope labeling of amino acids (SILAC) for quantitative-mass-spectrometry-based 
analysis of hepatic protein expression in miR-143
DOX
 mice. They analyzed the relative 
abundance of 2,043 proteins and detected peptide fragments of 1,463 proteins, of which 
214 proteins were upregulated and 48 were downregulated by 25% or more in liver 
extracts of miR-143
DOX
 mice when compared with control mice. They further analyzed 
the 48 downregulated proteins for predicted miR-143 binding sites in their 3’UTR. Five 
proteins showed predicted 3’UTR binding sites for miR-143 and one of them, 
oxysterol-binding-protein-related protein (ORP) 8, had three predicted miR-143 binding 
sites. The functional significance of the potential binding sites in the 3’UTR of ORP8 
were confirmed by luciferase reporter assays. Hepatic ORP8 protein expression was 
downregulated by 50% in miR-143
DOX
 mice and upregulated by 1.9-fold in 
miR-143-145 deficient mice when compared with controls. ORP depletion by a short 
interfering RNAs (siRNAs) technique in HepG2 cells revealed a significant reduction of 
insulin-stimulated AKT activation and downstream forkhead O-family (FOXO) 
phosphorylation. 
This study showed increased hepatic miR-143 expression in two different obesity 
mouse models and demonstrated that it affects hepatic insulin action and systemic 
glucose homeostasis in vivo by overexpression and knockout mouse models. The 
present study further provides evidence for miR-143-ORP8-dependent regulation of 
AKT signaling in obesity (Figure 1), and thus it is now time to examine miR-143, ORP8, 
and their regulated molecules as future therapeutic targets for obesity-associated insulin 
resistance and diabetes. 
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Schematic overview of the regulation of hepatic miR-143. 
Obesity results in induced expression of miR-143-145 in the liver. The 
involvement of miR-145 in glucose metabolism is unclear; however, upregulated 
miR-143 suppresses the translation of ORP8, which reduces the activation of Akt and 
impairs glucose homeostasis. The putative promoter region of the miR-143-145 cluster 
possesses numerous predicted consensus binding sites for FOXO transcription factors. 
Thus, there may be an autoregulatory loop in obesity-induced miR-143 expression, 
which is enhanced through the FOXO-dependent upregulation of hepatic miR-143 
under the situation of insulin resistance/AKT inhibition.  
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